Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625289 | 0.89 | MAPT (0.52) | NPSR1KDM4EMAPTTDP1POLB | |
| SCHEMBL4656404 | 0.86 | NPSR1 (0.50) | NPSR1KDM4EMAPTTDP1POLB | |
| SCHEMBL17742882 | 0.86 | ALDH1A1 (0.54) | KDM4EMAPTTDP1MAPK1ALDH1A1 | |
| SCHEMBL7754064 | 0.85 | NPSR1 (0.49) | NPSR1KDM4EMAPTTDP1POLB | |
| SCHEMBL1625485 | 0.83 | ALDH1A1 (0.51) | KDM4EMAPTTDP1MAPK1ALDH1A1 | |
| SCHEMBL2595990 | 0.83 | MAPT (0.49) | NPSR1KDM4EMAPTTDP1POLB | |
| SCHEMBL7342175 | 0.82 | SMN1; SMN2 (0.50) | NPSR1KDM4EMAPTTDP1POLB | |
| SCHEMBL8443380 | 0.82 | MAPT (0.54) | KDM4EMAPTTDP1MAPK1ALDH1A1 | |
| SCHEMBL1641895 | 0.81 | MAPT (0.47) | NPSR1MAPTTDP1MAPK1ALDH1A1 | |
| SCHEMBL19332218 | 0.81 | ALDH1A1 (0.46) | NPSR1KDM4EMAPTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2391604-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| CN-102264702-A | As P2X7Dihydropyridinone amides as modulators | — | 2011-11-30 | — | — | CN | disclosed |
| WO-2010072605-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072605-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | P2RX3, P2RX1, P2RY1 | NPSR1 32/4885KDM4E 2570/4885MAPT 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.